H7N9 is on everyone's map now. There is reasonable anxiety about what we will do if this becomes human to human and pandemic. News of FluCide and H7N9 will be repeated far and wide, whereas more news about "old news" viruses will get little attention.
Once a FluCide test is successful against H7N9 I think it will have a good effect on the stock.
Even though the company does not need money now, it is a good thing to build financial strength for the day when it may be needed for expansion and acquisitions.
It takes off because of the immediacy of the H7N9 problem. It is more deadly and there is mounting evidence that it transmits human to human with migratory birds acting as hosts in region to region spread.
This H7N9 is garnering the same attention H5N1 did in 2005-2006, until Tamiflu showed efficacy against it. Up until Tamiflu received emergency use approval, FluCude was in the running for priority development. H7N9 is Tamiflu resistant.
Added interest in FLUCIDE and NNVC will cause medicine companies like Johnson and Johnson, Merck, Phizer and Glasko Smith Klein to be more interested in FLUCIDE.
Some exccutives might then want to look more carefully into NNVC and the NNVC platform and FLUCIDE and then someone will want to own FLUCIDE before anyone else.
Then the Chinese will try to buy NNVC again and with more money.
Then the US based companies will want to own NNVC and FLUCIDE.
Then the Europeans and then the government will state we have to keep NNVC in the USA for jobs and taxes and manufacturing and then exports and return money. NNVC will have attention that was put on A123 only it will not be bankrupt. Then the price will go up and up and up.
Then we meet in Hawaii some day and talk about it and any new investments.
News 
Market Data 
Discover 
